EANO Meeting - Available all the time
Abstract presentations are highlighted with an A in the presentation number.
Intro: Federico Pessina
OS09.1 Quality of life in follow-up of adult patients with primary brain tumours
Florien Boele, United Kingdom
OS09.2 Health-related quality of life in children treated for brain tumours
Kim Bull, United Kingdom
OS09.3.A Caregiver burden of glioma patients: the impact of informal care
Robin van den Borg, Netherlands
OS09.4.A Health-related quality of life in low-grade glioma survivors 26 years after diagnosis
Florien Boele, United Kingdom
OS09.6.A Cognition and health-related quality of life in long time survivors of high-grade glioma
Marike Donders-Kamphuis, Netherlands
OS09.7.A Quality of life outcomes in patients with incidental and operated meningiomas: the QUALMS study
Sumirat Keshwara, United Kingdom
Intro: Florien Boele
OS10.1 Symptom Management Models and Non-pharmacological Symptom Management
Karin Piil, Denmark
OS10.2 Pharmacological management of symptoms after a brain tumour: Opening a psychiatrist's medicine box
Ally Rooney, United Kingdom
OS10.3.A Predicting delirium after craniotomy in neuro-oncology
Pablo Kappen, Netherlands
OS10.4.A The effects of SmartCare on neuro-oncology family caregivers' distress: a randomized controlled trial
Paula Sherwood, United States
OS10.5.A BrainWear: Longitudinal, objective assessment of physical activity in 42 HGG patients
Seema Dadhania, United Kingdom
OS10.6.A Supportive care needs of TYA childhood brain tumour survivors and their caregivers: a mixed methods study
Emma Nicklin, United Kingdom
OS10.7.A Localization patterns of language errors during direct electrical brain stimulation: a systematic review
Ellen Collée, Netherlands
OS10.8.A The effectiveness of antiepileptic drug duotherapies in glioma patients: a multicenter observational cohort study
Pim van der Meer, Netherlands
Intro: Stefan Pfister
OS11.1 Deregulation of chromatin modifier genes in medulloblastoma
Silvia Marino, United Kingdom
OS11.2 H3.3G34 mutations in gliomas: a case of mistaken identity
Nada Jabado, Canada
OS11.3 Modeling childhood brain tumors in vivo and with human organoids
Luca Tiberi, Italy
OS11.4 Developmental myelination and the origins of H3K27M+ diffuse midline glioma
Michelle Monje Deisseroth, United States
OS11.5.A PATZ1 fusions define a novel molecularly distinct CNS tumor entity with a broad histological spectrum
Karam Al Halabi, Germany
Intro: Benedikte Hasselbalch
OS12.1 First in human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) clinical trial in patients with recurrent high-grade glioma shows immunologic changes in injected tumors
E. Antonio Chiocca, United States
OS12.2 Combination of vaccines with checkpoint inhibitors for the treatment of brain tumors
Valerie Dutoit, Switzerland
OS12.3 Combining immune checkpoint inhibitors with stereotactic radiosurgery: is it safe and does it work?
Giuseppe Minniti, Italy
OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas
Michael Kilian, Germany
OS12.5.A The combination of the oncolytic virus Delta-24-ACT with a PD-L1 inhibitor results in anti-glioma effect and immune memory in preclinical models of glioma
Montse Puigdelloses, Spain
OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo
Michael Burger, Germany
OS12.7.A Characterization of intra-tumoral heterogeneity and differential immune activation during malignant progression of meningiomas on single cell level
Christina Blume, Germany
Intro: Christian Mawrin
OS13.1 In-vivo electroporation to dissect the biology of brain tumours
Paolo Salomoni, Germany
OS13.2 Modelling brain tumours one base at a time
Massimo Squatrito, Spain
Intro: Tareq Juratli
OS14.1 Residual tumor following resection of brain metastasis and the role of fluorescence
Barbara Kiesel, Austria
OS14.2 The evidence and safety of supramarginal resection in patient with glioblastoma
Frederico Pessina, Italy
OS14.3 Beyond grey scale B-mode ultrasound imaging to maximize the extent of resection
Francesco Prada, Italy
OS14.4.A The Neuroplastic Potential of the Human Brain Before and After Glioma Surgery: Towards Interventional Neurorehabilitation
Anujan Poologaindran, United Kingdom
OS14.5.A 3D high-resolution 7T MRSI for the metabolic imaging of high-grade gliomas
Gilbert Hangel, Austria
OS14.6.A GlioCova: Defining patient safety events for brain tumour patients undergoing neurosurgery
Radvile Mauricaite, United Kingdom
JS06.1 Overview of EORTC Brain Tumor Group studies
Matthias Preusser, Austria